-
Kenya's economy faces climate change risks: World Bank
-
Tokyo-bound United plane returns to Washington after engine fails
-
Deja vu? Trump accused of economic denial and physical decline
-
China's smaller manufacturers look to catch the automation wave
-
Hungary winemakers fear disease may 'wipe out' industry
-
Campaigning starts in Central African Republic quadruple election
-
'Stop the slaughter': French farmers block roads over cow disease cull
-
First urban cable car unveiled outside Paris
-
Why SpaceX IPO plan is generating so much buzz
-
US unseals warrant for tanker seized off Venezuelan coast
-
World stocks mostly slide, consolidating Fed-fuelled gains
-
Crypto firm Tether bids for Juventus, is quickly rebuffed
-
UK's king shares 'good news' that cancer treatment will be reduced in 2026
-
Can Venezuela survive US targeting its oil tankers?
-
Salah admired from afar in his Egypt home village as club tensions swirl
-
World stocks retrench, consolidating Fed-fuelled gains
-
Iran frees child bride sentenced to death over husband's killing: activists
-
World stocks consolidate Fed-fuelled gains
-
France updates net-zero plan, with fossil fuel phaseout
-
Stocks rally in wake of Fed rate cut
-
EU agrees recycled plastic targets for cars
-
British porn star to be deported from Bali after small fine
-
British porn star fined, faces imminent Bali deportation
-
Spain opens doors to descendants of Franco-era exiles
-
Indonesia floods were 'extinction level' for rare orangutans
-
Thai teacher finds 'peace amidst chaos' painting bunker murals
-
Japan bear victim's watch shows last movements
-
South Korea exam chief quits over complaints of too-hard tests
-
French indie 'Clair Obscur' dominates Game Awards
-
South Korea exam chief resigns after tests dubbed too hard
-
Asian markets track Wall St record after Fed cut
-
Laughing about science more important than ever: Ig Nobel founder
-
Vaccines do not cause autism: WHO
-
Crypto mogul Do Kwon sentenced to 15 years for fraud: US media
-
'In her prime': Rare blooming of palm trees in Rio
-
Make your own Mickey Mouse clip - Disney embraces AI
-
OpenAI beefs up GPT models in AI race with Google
-
Dark, wet, choppy: Machado's secret sea escape from Venezuela
-
Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
-
2024 Eurovision winner Nemo returns trophy over Israel's participation
-
US bringing seized tanker to port, as Venezuela war threats build
-
Make your own AI Mickey Mouse - Disney embraces new tech
-
Time magazine names 'Architects of AI' as Person of the Year
-
Floodworks on Athens 'oasis' a tough sell among locals
-
OpenAI, Disney to let fans create AI videos in landmark deal
-
German growth forecasts slashed, Merz under pressure
-
Thyssenkrupp pauses steel production at two sites citing Asian pressure
-
ECB proposes simplifying rules for banks
-
Stocks mixed as US rate cut offset by Fed outlook, Oracle earnings
-
Desert dunes beckon for Afghanistan's 4x4 fans
Once-taboo ketamine booms for US at-home mental care
Americans are paying to get a star of the psychedelic medicine movement –- ketamine -– shipped to them for at-home mental health treatments that are being called both a breakthrough and a gamble.
A pandemic-spurred easing of prescription rules helped fuel a jump in telemedicine offerings of ketamine, an anesthetic that was once a taboo party drug but has become a buzzed-about tool against depression.
Yet long-term, large-scale studies of ketamine's medical impact are limited, leaving some experts concerned that an unregulated online boom could result in mishaps or a regulatory crackdown.
"This has to be rolled out slowly," said Boris Heifets, a Stanford University assistant professor of anesthesiology. "The risk is that we are scaling the fix but not the solution, which is a much more integrated approach to mental health."
Ketamine has been available in the United States since the 1970s as an anesthetic called a "dissociative" because of the hallucinogenic effects that have helped make it a rave culture drug.
It's legal for US doctors to prescribe, while some other psychedelics getting renewed attention for mental health uses like LSD or MDMA (also called ecstasy) are classified as having no medical utility and a high risk for abuse.
In this context, recent years have seen an uptick in clinics offering in-person intravenous ketamine treatments for depression, anxiety or chronic pain, though regulations and practices vary across American states.
- Ketamine 'babysitter' -
Then came the pandemic, which resulted in US authorities allowing doctors to remotely prescribe drugs like ketamine that previously required an in-person visit.
An increasing number of companies, some already doing in-clinic treatments, began offering to evaluate clients online and to send the drugs for home use to approved candidates.
Nue Life, which launched about a year ago, is one of those firms. Its CEO Juan Pablo Cappello estimated it has served over 3,000 ketamine patients so far.
"If you actually drill down on the sort of potentials for abuse here, you realize of course they exist, but we're creating a standard of care to make that quite unlikely," he told AFP.
For example, he noted clients are instructed to have an adult "babysitter" watch over them for the roughly 90 minutes the drug experience lasts, and he reasoned that people simply looking for ketamine could get it cheaper on the street.
Clients of the service, which costs $1,250 for a package providing six ketamine experiences, are encouraged but not obligated to couple it with therapy, Cappello said.
"The at-home telemedicine model, I would argue, is actually safer and more effective for patients," allowing more patients "to actually take advantage of these therapies," he added.
Heifets, the Stanford researcher, noted that making ketamine more available carries risks -- including the chances that authorities would tighten access if an at-home treatment resulted in some sort of tragedy.
- 'Change your life' -
US regulators in 2019 approved a type of ketamine specifically for adults with treatment-resistant depression, though with stringent rules like requiring patients to be monitored by a health care provider for at least two hours after their dose.
Americans have "a hair trigger for problem-solving through litigation," Heifets noted of the potential for lawsuits if things go wrong.
He was part of a team that analyzed the real-world effectiveness of intravenous ketamine therapy -- which can involve higher doses than the at-home services –- and reported most patients improved, though about eight percent said depressive symptoms worsened after treatment.
"We have very, very little evidence for our understanding of how effective ketamine is for depression at scale," he added.
Yet for people like 36-year-old New Yorker Philip Markle, who underwent an at-home treatment with a company called Mindbloom, ketamine is a profoundly useful tool.
Over his long battle with depression, the performer and comedian has tried medication, psychedelics like LSD, and talk therapy since the age of 12, but found something unique in ketamine.
Rather than the short-lived sense of change other treatments provided, ketamine imparted a sense of clarity and of helpful self-acceptance -– not the heavy effects he'd experienced with other psychedelics.
"It felt like if any drug could be administered through the mail, and you could do a psychedelic that could change your life, on your own, this would be the one," he told AFP.
M.Davis--CPN